help button home button
AJRCCM
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by RODRIGO, G. J.
Right arrow Articles by RODRIGO, C.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by RODRIGO, G. J.
Right arrow Articles by RODRIGO, C.

Am. J. Respir. Crit. Care Med., Volume 161, Number 6, June 2000, 1862-1868

First-Line Therapy for Adult Patients with Acute Asthma Receiving a Multiple-Dose Protocol of Ipratropium Bromide Plus Albuterol in the Emergency Department

GUSTAVO J. RODRIGO and CARLOS RODRIGO

Departamento de Emergencia, Hospital Central de las FF.AA, and Unidad de Cuidado Intensivo, Asociación Española 1a de Socorros Mutuos, Montevideo, Uruguay

We designed a larger, double-blind, randomized, prospective trial to test our hypothesis that patients with acute asthma given combination high dose therapy with ipratropium bromide (IB) and beta 2-agonists will have greater improvement in pulmonary function and fewer hospital admissions than those given beta 2-agonists alone. One hundred eighty patients (mean age ± SD, 34.3 ± 10.5 yr) who presented to an emergency department (ED) for treatment of an exacerbation of asthma (baseline FEV1 < 50% of predicted) were assigned in a randomized, double-blind fashion to receive albuterol and placebo (n = 92) or albuterol and IB (n = 88). Both drugs were administered through a metered-dose inhaler and spacer at 10-min intervals for 3 h (24 puffs or 2,880 µg of albuterol and 504 µg of IB each hour). Primary outcome measures were improvement in pulmonary function (FEV1 or peak expiratory flow [PEF]), and hospital admission rates. In both groups, pulmonary function improved significantly over baseline values (p < 0.01). Subjects who received IB had an overall 20.5% (95% CI: 2.6 to 38.4%) (p = 0.02) greater improvement in PEF and a 48.1% (95% CI: 19.8 to 76.4%) (p = 0.001) greater improvement in FEV1 from the control group. At the end of protocol (3 h), 39% (n = 36) of patients in the control group and 20% (n = 18) in the IB group were admitted (p = 0.01). The use of high doses of IB reduced the risk of hospital admission 49% (relative risk = 0.51, 95% CI: 0.31 to 0.83). Five (95% CI: 3 to 17) patients would need to be treated with high doses of IB to prevent a single admission. Kaplan-Meier-estimated curves of the proportion of patients who reached the discharge threshold during the 3 h of treatment, showed a significant difference in favor of the IB group (log-rank test = 0.005). A subgroup analysis showed that patients most likely to benefit from the addition of high doses of IB were those with more severe obstruction (FEV1 =< 30% of predicted) and long duration of symptoms before the ED presentation (>=  24 h). On the contrary, previous use of inhaled beta 2-agonists did not modify the admission rate and the pulmonary function response to IB. In conclusion, our data support a substantial therapeutic benefit from the addition of IB to albuterol administered in high doses through MDI plus spacer, particularly in patients with FEV1 less than 30%, and with long duration of symptoms before the ED presentation (>=  24 h).




This article has been cited by other articles:


Home page
 Eur Respir JHome page
E. D. Bateman, S. S. Hurd, P. J. Barnes, J. Bousquet, J. M. Drazen, M. FitzGerald, P. Gibson, K. Ohta, P. O'Byrne, S. E. Pedersen, et al.
Global strategy for asthma management and prevention: GINA executive summary
Eur. Respir. J., January 1, 2008; 31(1): 143 - 178.
[Abstract] [Full Text] [PDF]

Home page
 Emerg. Med. J.Home page
K. Najafizadeh, H. Sohrab Pour, M. Ghadyanee, M. Shiehmorteza, M. Jamali, and S. Majdzadeh
A randomised, double-blind, placebo-controlled study to evaluate the role of formoterol in the management of acute asthma
Emerg. Med. J., May 1, 2007; 24(5): 317 - 321.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Physiol. Lung Cell. Mol. Physiol.Home page
N. G. Verbout, J. K. Lorton, D. B. Jacoby, and A. D. Fryer
Atropine pretreatment enhances airway hyperreactivity in antigen-challenged guinea pigs through an eosinophil-dependent mechanism
Am J Physiol Lung Cell Mol Physiol, May 1, 2007; 292(5): L1126 - L1135.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
H. K. Reddel and D. J. Barnes
Pharmacological strategies for self-management of asthma exacerbations.
Eur. Respir. J., July 1, 2006; 28(1): 182 - 199.
[Abstract] [Full Text] [PDF]

Home page
 ThoraxHome page
G J Rodrigo and J A Castro-Rodriguez
Anticholinergics in the treatment of children and adults with acute asthma: a systematic review with meta-analysis
Thorax, September 1, 2005; 60(9): 740 - 746.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
G. J. Rodrigo
Comparison of Inhaled Fluticasone with Intravenous Hydrocortisone in the Treatment of Adult Acute Asthma
Am. J. Respir. Crit. Care Med., June 1, 2005; 171(11): 1231 - 1236.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, C. Rodrigo, and J. B. Hall
Acute Asthma in Adults: A Review
Chest, March 1, 2004; 125(3): 1081 - 1102.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. S. Jalba, G. J. Rodrigo, C. Rodrigo, C. A. Camargo Jr., M.-P. Malice, S. A. Green, and T. F. Reiss
Intravenous Montelukast in Acute Asthma
Am. J. Respir. Crit. Care Med., January 1, 2004; 169(1): 130 - 131.
[Full Text]

Home page
 Am. J. Respir. Crit. Care Med.Home page
E. R. McFadden Jr.
Acute Severe Asthma
Am. J. Respir. Crit. Care Med., October 1, 2003; 168(7): 740 - 759.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo and C. Rodrigo
Triple Inhaled Drug Protocol for the Treatment of Acute Severe Asthma
Chest, June 1, 2003; 123(6): 1908 - 1915.
[Abstract] [Full Text] [PDF]

Home page
 Eur Respir JHome page
J.M. Wraight, R.J. Hancox, G.P. Herbison, J.O. Cowan, E.M. Flannery, and D.R. Taylor
Bronchodilator tolerance: the impact of increasing bronchoconstriction
Eur. Respir. J., May 1, 2003; 21(5): 810 - 815.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, C. Rodrigo, M. Noppen, and R. Silverman
IV Magnesium in the Treatment of Acute Severe Asthma?
Chest, April 1, 2003; 123(4): 1314 - 1316.
[Full Text] [PDF]

Home page
 ChestHome page
C. A. Manthous
Heliox for Status Asthmaticus?
Chest, March 1, 2003; 123(3): 676 - 677.
[Full Text] [PDF]

Home page
 The Annals of PharmacotherapyHome page
G. M Peterson, P. J Boyles, M. D Bleasel, and J. H Vial
Ipratropium Treatment of Acute Airways Disease
Ann. Pharmacother., March 1, 2003; 37(3): 339 - 344.
[Abstract] [Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
J. M. FitzGerald
Broadening the Therapeutic Options in Acute Asthma
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 488 - 489.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
C. A. Camargo Jr., H. A. Smithline, M.-P. Malice, S. A. Green, and T. F. Reiss
A Randomized Controlled Trial of Intravenous Montelukast in Acute Asthma
Am. J. Respir. Crit. Care Med., February 15, 2003; 167(4): 528 - 533.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
R. A. Silverman, H. Osborn, J. Runge, E. J. Gallagher, W. Chiang, J. Feldman, T. Gaeta, K. Freeman, B. Levin, N. Mancherje, et al.
IV Magnesium Sulfate in the Treatment of Acute Severe Asthma* : A Multicenter Randomized Controlled Trial
Chest, August 1, 2002; 122(2): 489 - 497.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo and C. Rodrigo
The Role of Anticholinergics in Acute Asthma Treatment* : An Evidence-Based Evaluation
Chest, June 1, 2002; 121(6): 1977 - 1987.
[Abstract] [Full Text] [PDF]

Home page
 JAMAHome page
D. B. Jacoby
Virus-Induced Asthma Attacks
JAMA, February 13, 2002; 287(6): 755 - 761.
[Abstract] [Full Text] [PDF]

Home page
 ChestHome page
G. J. Rodrigo, C. Rodrigo, and H. A. Werner
Status Asthmaticus in Children : Evidence-Based Recommendations
Chest, February 1, 2002; 121(2): 667 - 669.
[Full Text] [PDF]

Home page
 Am. J. Respir. Crit. Care Med.Home page
M. J. TOBIN
Asthma, Airway Biology, and Allergic Rhinitis in AJRCCM 2000
Am. J. Respir. Crit. Care Med., November 1, 2001; 164(9): 1559 - 1580.
[Full Text] [PDF]

Home page
 BMJHome page
M. FitzGerald
Extracts from ""Clinical Evidence"": Acute asthma
BMJ, October 13, 2001; 323(7317): 841 - 845.
[Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Proc. Am. Thorac. Soc. Am. J. Respir. Cell Mol. Biol.
Copyright © 2000 American Thoracic Society 		  New Orleans Int'l Conf